{"title":"[STATE-OF-THE-ART OF GLOBAL START-UP INVESTMENT FOR ALLERGY AND IMMUNOLOGY 2022].","authors":"Takeya Adachi, Motoshi Hayano, Yasunori Ito, Takenori Inomata, Yasushi Ogawa, Keigo Kainuma, Keiko Kan-O, Yosuke Kurashima, Yu Kuwabara, Masafumi Sakashita, Sakura Sato, Yasuhiro Tomita, Saeko Nakajima, Masaki Futamura, Katsunori Masaki, Mayumi Tamari, Motohiro Ebisawa, Hideaki Morita","doi":"10.15036/arerugi.73.268","DOIUrl":"https://doi.org/10.15036/arerugi.73.268","url":null,"abstract":"<p><strong>Background: </strong>In 2022, the \"New Capitalism Grand Design and Implementation Plan\" was adopted in Japan, emphasizing the promotion and environmental development of startups. Given this context, an investigation into the startup and investment landscape in the allergy sector, both domestically and internationally, becomes imperative.</p><p><strong>Methods: </strong>We analyzed 156 allergy-related startups from Japan, the US, and Europe from 2010 to 2021. Data on corporate information and investment trends were extracted from databases and VC websites.</p><p><strong>Results: </strong>The total investment reached approximately 7.2 billion USD, with a ratio of 20:6:1 for the US, Europe, and Japan, respectively. The US showed a decline post its peak from 2016-2018, while Europe and Japan experienced growth. Notably, the US primarily invested in biopharmaceuticals for atopic dermatitis and food allergies, Europe in asthma-related apps, and Japan in healthcare apps and cross-border startups.</p><p><strong>Discussion and conclusion: </strong>While Japan's investment environment in the allergy sector remains in its nascent stages and has room for development, the US and Europe are evidently ahead. Considering the rise of startups and funding limitations in Japan, external funding from regions like the US becomes a potential avenue. These findings are anticipated to contribute to the strategic activation of startups in allergy research and development.</p>","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"73 3","pages":"268-278"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[PROSPECTS FOR THE COMMITMENT OF GENETIC BIG DATA TO ALLERGY MEDICINE].","authors":"Hideyasu Yamada","doi":"10.15036/arerugi.73.21","DOIUrl":"https://doi.org/10.15036/arerugi.73.21","url":null,"abstract":"","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"73 1","pages":"21-25"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139973826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[A NATIONWIDE SURVEY ON THE CURRENT IMPLEMENTATION STATUS OF MEDICAL PRACTICES FOR ADULT PATIENTS WITH FOOD ALLERGIES IN JAPAN].","authors":"Sakura Sato, Yuma Fukutomi, Chizuko Sugizaki, Shintaro Suzuki, Akiko Yagami, Noriyuki Yanagida, Motohiro Ebisawa","doi":"10.15036/arerugi.73.1200","DOIUrl":"https://doi.org/10.15036/arerugi.73.1200","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to elucidate the current implementation status of medical practices for adult patients with food allergies (FA) in Japan.</p><p><strong>Methods: </strong>A survey was conducted from October to December 2021 at the allergy specialist training facilities of the Japanese Society of Allergology, examining the status of medical practices for patients with food allergies in 2019.</p><p><strong>Results: </strong>Of the 819 facilities, 273 (33%) treated childhood or adult patients with FA, 8% did not treat patients with FA, and 59% did not respond to the survey. Among the facilities, 24% treated adult patients with FA across various specialties: dermatology (45%), pediatrics (37%), otolaryngology (16%), internal medicine (14%), and ophthalmology (0%). The total number of adult patients with FA at the 273 facilities was 9260, with 37% having childhood-onset and 63% having adult-onset. Among childhood-onset cases, 99% were treated in pediatric departments. The oral food challenge (OFC) was available at 198 facilities (73%), including pediatrics (94%), dermatology (66%), internal medicine (30%), and otolaryngology facilities (0%). A total of 934 OFCs were conducted in adults, of which 63% were performed in pediatric departments.</p><p><strong>Conclusion: </strong>Medical practices for adult patients with FA in Japan remain insufficient, with inadequate transitional care for childhood-onset cases. Strengthening medical support, including OFC for adult patients with FA, and establishing seamless transitional care is necessary.</p>","PeriodicalId":35521,"journal":{"name":"Japanese Journal of Allergology","volume":"73 10","pages":"1200-1209"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
